Omnicell Pinned at Neutral (CFN) (MCK) (OMCL)
Following a strong third-quarter result, we have reiterated our long-term ‘Neutral’ recommendation on Omnicell ( OMCL ), provider of end-to-end automation solutions for the medication-use process, with a target price of $16.00. In the third quarter of 2012, Omnicell reported earnings per share of 22 cents, well above the Zacks Consensus Estimate of 13 cents. Revenues in the quarter (including the results of MTS Medication Technologies) increased 30.9% year over year to $84.3 million, nominally missing the Zacks Consensus Estimate of $85 million […]